Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announces that it has entered into an Advance Agreement with Teyame AI LLC, a St Kitts and Nevis corporation ("Teyame"), as part of its planned acquisition of the shares of Teyame 360 SL and Datono Mediacion SL, companies incorporated in Spain ("Assets"), which are run together as a Spain-based leader in AI-powered omnichannel customer experience (CX) solutions. This acquisition would position the Company as a global force in AI-powered customer and patient engagement.
The proposed transaction contemplates up to approximately $50 million of total consideration, consisting of a combination of cash, shares of the Company's common stock, shares of non-voting convertible preferred stock, and contingent earnout-based equity consideration, subject to the final terms of a definitive purchase agreement. The parties currently anticipate targeting a closing in the first quarter of 2026, subject to the negotiation and execution of a definitive purchase agreement, completion of due diligence, required shareholder approval, and other customary closing conditions. This communication does not constitute a solicitation of any proxy, vote or approval.
Based on financial information the Company has received from Teyame, the Company expects the Assets to generate approximately $34 million in incremental annual revenue and $4.2 million in incremental EBITDA for fiscal year 2025. The planned acquisition represents a pivotal moment in HCTI's evolution from healthcare IT provider to comprehensive digital health innovator and is expected to significantly enhance HCTI's financial performance and shareholder value.
"The transaction will bring real world lived experience of Agentic Gen AI and is about to change the game for HCTI. It's where the rubber meets the road in AI" added David Ayanoglou, Chief Financial Officer of HCTI.
'We are pleased to take this decisive step with the signing of the binding advance agreement. Integrating these AI-powered engagement platforms with HCTI's healthcare technologies positions us to deliver a next-generation, intelligent ecosystem for patients, providers, and global markets."— Sujatha Ramesh, Chief Operating Officer, Principal Executive Officer, and Director, Board of Directors, HCTI.
This planned acquisition is slated to be a critical step in HCTI's broader strategy focused on:
This strategic acquisition will combine HCTI's deep healthcare technology expertise with the acquired Assets' AI automation customer engagement platform(s), so that an integrated ecosystem can be created where every patient touchpoint would become intelligent, personalized, and outcome focused.